{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T10:28:44Z","timestamp":1758450524341,"version":"3.44.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.metabol.2014.04.014","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T13:45:21Z","timestamp":1399383921000},"page":"1049-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes"],"prefix":"10.1016","volume":"63","author":[{"given":"Chin-Hsiao","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.014_bb0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.metabol.2011.06.020","article-title":"The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients","volume":"61","author":"Lee","year":"2012","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.metabol.2011.11.015","article-title":"Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan","volume":"61","author":"Tseng","year":"2012","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.014_bb0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2337\/dc10-1640","article-title":"Diabetes and risk of prostate cancer: A study using the National Health Insurance","volume":"34","author":"Tseng","year":"2011","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2014.04.014_bb0030","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00125-011-2171-z","article-title":"Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan","volume":"54","author":"Tseng","year":"2011","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.metabol.2014.04.014_bb0035","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.metabol.2011.03.005","article-title":"Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis","volume":"60","author":"Rosato","year":"2011","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2014.04.014_bb0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.metabol.2009.11.019","article-title":"Metabolic syndrome and risk of death from cancers of the digestive system","volume":"59","author":"Matthews","year":"2010","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.014_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jdi.12208","article-title":"Cancer biology in diabetes","volume":"5","author":"Sen","year":"2014","journal-title":"J Diabetes Invest"},{"issue":"5","key":"10.1016\/j.metabol.2014.04.014_bb0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00125-011-2051-6","article-title":"Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies","volume":"54","author":"Larsson","year":"2011","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.metabol.2014.04.014_bb0055","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.7314\/APJCP.2013.14.11.6523","article-title":"Cigarette smoking and other risk factors for kidney cancer death in a Japanese population: Japan Collaborative Cohort Study for evaluation of cancer risk (JACC study)","volume":"14","author":"Washio","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0060","first-page":"627","article-title":"Clinical research on the correlations between type 2 diabetes mellitus and renal clear cell carcinoma","volume":"51","author":"Song","year":"2013","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jdiacomp.2013.01.004","article-title":"Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis","volume":"27","author":"Bao","year":"2013","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.metabol.2013.01.014","article-title":"Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies","volume":"62","author":"Thakkar","year":"2013","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2014.04.014_bb0075","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.metabol.2010.09.012","article-title":"Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort","volume":"60","author":"Baur","year":"2011","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2014.04.014_bb0080","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.metabol.2011.05.002","article-title":"Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study","volume":"60","author":"Buchs","year":"2011","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2014.04.014_bb0085","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.metabol.2011.03.011","article-title":"Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk","volume":"60","author":"La Vecchia","year":"2011","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.014_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.metabol.2004.07.010","article-title":"Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment","volume":"54","author":"Inaba","year":"2005","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0095","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3748\/wjg.v20.i7.1701","article-title":"Diabetes and gastric cancer: the potential links","volume":"20","author":"Tseng","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.014_bb0100","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.urology.2004.10.019","article-title":"Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma","volume":"65","author":"Yuan","year":"2005","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.014_bb0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/bbrc.2001.5640","article-title":"Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists","volume":"287","author":"Inoue","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.014_bb0110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12032-011-9982-0","article-title":"Pioglitazone, etoricoxib, interferon-\u03b1, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial","volume":"29","author":"Walter","year":"2012","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/dc10-1067","article-title":"Cohort study of pioglitazone and cancer incidence in patients with diabetes","volume":"34","author":"Ferrara","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0120","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","volume":"55","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.014_bb0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.diabet.2012.06.003","article-title":"Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis","volume":"38","author":"Colmers","year":"2012","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.014_bb0130","first-page":"1","article-title":"A review on thiazolidinediones and bladder cancer in human studies","volume":"32","author":"Tseng","year":"2014","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0135","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"issue":"9493","key":"10.1016\/j.metabol.2014.04.014_bb0140","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.metabol.2014.04.014_bb0145","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.metabol.2014.04.014_bb0150","doi-asserted-by":"crossref","first-page":"e53096","DOI":"10.1371\/journal.pone.0053096","article-title":"Thyroid cancer risk is not increased in diabetic patients","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2014.04.014_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2407-13-7","article-title":"Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan","volume":"13","author":"Tseng","year":"2013","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.canep.2013.03.013","article-title":"Rosiglitazone is not associated with an increased risk of bladder cancer","volume":"37","author":"Tseng","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0165","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dmrr.2422","article-title":"Diabetes is not an independent risk factor for hepatocellular carcinoma","volume":"29","author":"Tseng","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.014_bb0170","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.clgc.2013.08.004","article-title":"Human insulin does not increase prostate cancer risk in Taiwanese","volume":"12","author":"Tseng","year":"2014","journal-title":"Clin Genitourin Cancer"},{"author":"Department of Biostatistics, Vanderbilt University","key":"10.1016\/j.metabol.2014.04.014_bb0175"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.014_bb0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jfma.2011.10.003","article-title":"Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.014_bb0185","first-page":"368","article-title":"Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies","volume":"30","author":"Tseng","year":"2012","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.014_bb0190","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/dc11-1449","article-title":"Pioglitazone and bladder cancer: a population-based study of Taiwanese","volume":"35","author":"Tseng","year":"2012","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2014.04.014_bb0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.014_bb0200","doi-asserted-by":"crossref","first-page":"120","DOI":"10.47102\/annals-acadmedsg.V42N3p120","article-title":"Kidney cancer and diabetes mellitus: a population-based case-control study in Taiwan","volume":"42","author":"Lai","year":"2013","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.014_bb0205","doi-asserted-by":"crossref","first-page":"c143","DOI":"10.1159\/000315883","article-title":"Confounding","volume":"116","author":"van Stralen","year":"2010","journal-title":"Nephron Clin Pract"},{"issue":"11","key":"10.1016\/j.metabol.2014.04.014_bb0210","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/bjc.2012.136","article-title":"Alcohol intake and renal cell cancer risk: a meta-analysis","volume":"106","author":"Song","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.014_bb0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canep.2011.09.006","article-title":"Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study","volume":"36","author":"Wang","year":"2012","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.014_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.metabol.2014.04.014_bb0225","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-2407-14-196","article-title":"Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.014_bb0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2009.07.006","article-title":"Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients","volume":"59","author":"Oz Gul","year":"2010","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.014_bb0235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diabres.2004.11.003","article-title":"Pioglitazone with sulfonylurea: Glycemic and lipid effects in Taiwanese type 2 diabetic patients","volume":"70","author":"Tseng","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.014_bb0240","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/VHRM.S4664","article-title":"Redefining the role of thiazolidinediones in the management of type 2 diabetes","volume":"5","author":"Barnett","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.014_bb0245","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514001383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514001383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:03:44Z","timestamp":1758427424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0026049514001383"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.04.014","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}